Biodexa Pharmaceuticals PLC
BDRX1.240USD
-0.060-4.62%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
7.68B시가총액
7.11P/E TTM
자세한 내용은 Biodexa Pharmaceuticals PLC 회사
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC 정보
종목 코드 BDRX
회사 이름Biodexa Pharmaceuticals PLC
상장일Dec 08, 2014
CEOStamp (Stephen A)
직원 수- -
유형Depository Receipt
회계 연도 종료Dec 08
주소1 Caspian Point
도시ABINGDON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United Kingdom
우편 번호CF10 4DQ
전화4401235888300
웹사이트https://www.biodexapharma.com/
종목 코드 BDRX
상장일Dec 08, 2014
CEOStamp (Stephen A)
Biodexa Pharmaceuticals PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
Dr. Sijmen (Simon) De Vries, M.D.
Dr. Sijmen (Simon) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
Belgium
381.00K
100.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Mon, Feb 2
마지막 업데이트: Mon, Feb 2
주주
주주 유형
주주
주주
비율
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
기타
96.24%
주주
주주
비율
Brio Capital Management LLC
2.71%
Abbe (Richard)
0.39%
UBS Financial Services, Inc.
0.31%
GAMMA Investing LLC
0.29%
District 2 Capital LP
0.07%
기타
96.24%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
2.99%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.31%
Hedge Fund
0.07%
Bank and Trust
0.03%
Research Firm
0.02%
기타
95.63%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
25
26.99K
4.95%
--
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
2023Q3
18
57.00
107.67%
+15.00
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
GAMMA Investing LLC
1.78K
0.29%
+425.00
+31.43%
Dec 31, 2025
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
UBS Switzerland AG
6.92K
1.12%
+6.73K
+3379.90%
Sep 30, 2025
SBI Securities Co., Ltd.
115.00
0.02%
-452.00
-79.72%
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
5.00
0%
-2.00
-28.57%
Sep 30, 2025
Contravisory Investment Management, Inc.
--
0%
-4.00
-100.00%
Jun 30, 2025
Geode Capital Management, L.L.C.
--
0%
-8.00
-100.00%
Apr 30, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
날짜
배당락일
유형
비율
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
더 보기
